Development and validation of a high-performance liquid chromatography assay for voriconazole.
about
Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.Direct injection HPLC micro method for the determination of voriconazole in plasma using an internal surface reversed-phase column.Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy.Fast and reliable determination of voriconazole in human plasma by LC-APCI-MS/MS.Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.Voriconazole pharmacokinetics in liver transplant recipients.Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjectsAccelerated metabolism of voriconazole and its partial reversal by cimetidineSerial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation.Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysisHallucinations during voriconazole therapy.Antifungal therapeutic drug monitoring: established and emerging indications.Voriconazole therapeutic drug monitoring: focus on safety.Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections.An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old.Development and Validation of Stability Indicating RP-HPLC Method for VoriconazoleDevelopment and Validation of Voriconazole Concentration by LC-MS-MS: Applied in Clinical Implementation.Determination of Voriconazole Concentrations in Serum by GC-MS.Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography.A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluidIsocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum.Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis.Development and Validation of a RP-HPLC Method for Determination of Cyclosporine in Capsule.Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype.CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.Effect of voriconazole on the pharmacokinetics of diclofenac.Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight.Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients
P2860
Q30981299-449B5E22-C004-44FE-8ED3-63EF6A98FCD1Q31115252-5F2E1F59-100D-4BA4-A7F6-C4CA6BDF37B3Q33257899-8262BB07-2D4B-4489-BD92-C16002F375DEQ33448151-C882BAC8-5B9A-4E01-B7DD-7B9C935DFC26Q33608028-CA55F8D4-8495-40E3-8C32-EA77CB6D8BAFQ33613685-AE9CA1CD-A359-409C-AF94-55EF634AEC08Q35635830-8D05A5F1-9D54-44D5-BB06-4BF36F13C7B6Q36024937-82AE1C98-4720-427E-B912-581B3BC4C117Q37144774-3FE614AE-09EC-42FA-B656-9B2CCAA5ECACQ37190736-774208B4-2CF8-4CF1-BD37-9462C30D520DQ37204192-1FCC36D0-8F96-45FA-B7A6-FEC936CE1ACCQ37307500-FF3FF8BD-2611-4552-AA21-C07E0B724523Q37310029-704085C8-0D7B-48F9-8344-78D3A455CD1FQ37658869-0369758A-387C-4FBB-9592-3D91505F25D1Q39215244-DE1B25DD-3862-494C-9414-30A7E185133BQ39466921-E806E598-0989-4C6C-AA5F-DA4E5FA7495DQ40430792-162C6527-5B4D-4100-A13C-66FCB2963722Q40638888-598BD061-1365-4560-ABFF-93EAA9CA455BQ41009508-B16A8193-5EF3-48B0-8163-9FBA4831B6F4Q41868987-0F26815E-B498-4392-9567-F36EE35CE667Q41907424-AC9543A6-0358-4E3F-A898-E827AEF03E3BQ41936899-BE6C5702-3EC8-47AC-B777-670090630A6FQ42064852-14C36562-D802-44DB-A02E-002561B9F0F9Q42128485-F1E17352-511D-4724-BC50-39012A217FF2Q42408726-E4C5D1AA-3761-4640-A0B2-97AD6B1022A3Q43151688-2A19859A-0084-4922-877C-FB1866A55D4BQ44273424-42CF45A1-049D-4010-A729-5D12B080032CQ44705704-1BF6BDB2-A37A-4AAF-81F3-A50A74FE0E0DQ45227047-5DAF5982-D7B4-4820-9525-41FE47262091Q46885397-BDB83F5A-8EE7-4667-A2BC-2D9F81237CD2Q47327923-8C759642-5580-44DB-A45F-395E1EDD219DQ57611765-88632AC7-6C59-44B0-8002-DDA57C743A1C
P2860
Development and validation of a high-performance liquid chromatography assay for voriconazole.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Development and validation of ...... graphy assay for voriconazole.
@en
Development and validation of ...... graphy assay for voriconazole.
@nl
type
label
Development and validation of ...... graphy assay for voriconazole.
@en
Development and validation of ...... graphy assay for voriconazole.
@nl
prefLabel
Development and validation of ...... graphy assay for voriconazole.
@en
Development and validation of ...... graphy assay for voriconazole.
@nl
P2093
P1476
Development and validation of ...... graphy assay for voriconazole.
@en
P2093
Deanna A Sutton
Gennethel J Pennick
Martin Clark
Michael G Rinaldi
P2860
P304
P356
10.1128/AAC.47.7.2348-2350.2003
P407
P577
2003-07-01T00:00:00Z